

Regulatory Announcement

Company Akers Biosciences, Inc.
TIDM AKR
Headline Director/PDMR Shareholding
Released 14:54 25-Jul-07
Number 8560A

Akers Biosciences, Inc. (“ABI” or the “Company”)

Officer Shareholding & Additional Listing

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products announces that a Company Officer and a former Officer have, on 23 July 2007, increased their shareholdings in the Company by way of a subscription to New Ordinary shares.

Leroy J. Meyers, VP Operations has invested \$8,816 by way of a subscription to 40,000 New Ordinary Shares at the closing price on 23 July 2007 of 10.75 pence. Mr. Meyers' shareholdings now total 40,000 common shares, representing less than .001% of the total issued share capital of the Company.

Arthur W. Mullin, former Chief Financial Officer, has converted \$11,020 of fees into 50,000 New Ordinary Shares at the closing price on 23 July 2007 of 10.75 pence. Mr. Mullin's shareholdings now total 50,000 common shares, representing less than .001% of the total issued share capital of the Company.

Application has been made to the London Stock Exchange for 90,000 New Ordinary Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to trading, such admission expected to take place on 31 July 2007.

The exchange rate used for these transactions was \$2.05:£1.00.

Enquiries:

Thomas A. Nicolette, President & CFO
Akers Biosciences, Inc.
Tel. 001 856 848 8698

Ben Simons
Hansard Group
Tel. 020 7245 1100
END